Wheat Ridge, Colorado (PRWEB) February 12, 2013
Drug and alcohol testing industry leader, Lifeloc Technologies today announced the immediate availability of its on-line DOT Urine Specimen Collector qualification training course. The new course is one of the first of its kind to offer web-based Urine Specimen Collector instruction to meet the DOT requirements for Urine Sample Collection as outlined in the 49 CFR Part 40 regulations.
Amy Evans, Workplace Business Manager for Lifeloc, said, "The success of our online Breath Alcohol Technician Training and Reasonable Suspicion Supervisor Training encouraged us to develop a web based version of the traditional classroom based specimen collection training and certification. We now offer online versions of the three most important drug and alcohol testing qualification courses.
Barry Knott, Lifeloc president added, " The combination of our on-line procedural training courses and our North American network of over 25 Lifeloc Master Trainers uniquely positions Lifeloc to support the substance abuse industry with the convenience and affordability of web-based training plus the experience of highly qualified local substance abuse experts."
Users retain full access to all course materials and downloads for the life of their certifications. DOT changes are updated into course materials as they happen and sent to certificate holders through automatic email notifications.
Volume and multiple course discounts are available to Third Party Administrators (TPAs) and Corporations. All course content is SCORM compliant and can be private branded and offered through internal company training systems.
About Lifeloc Technologies
Lifeloc Technologies is a trusted international manufacturer of professional breath alcohol testing instruments (breathalyzers). Lifeloc also offers comprehensive online and classroom training, supplies and drug screening products. We manufacture Law Enforcement Portable Breath Alcohol Testers (PBTs) and Workplace Evidential Breath Testers (EBTs). Lifeloc evidential and screening devices are approved by the U.S. DOT and other state and international regulatory agencies. More information about Lifeloc is available at http://www.lifeloc.com.
This release includes statements that constitute “forward-looking statements” under the securities laws. Forward-looking statements often contain words such as “believe”, “expect,” “plans”, “strategy”, “prospects”, “estimate”, “project”, “target”, “anticipate”, “will”, “should”, “see,” “guidance”, “confident” and similar terms. Forward-looking statements may include, among other things, statements relating to future and estimated sales, earnings, cash flow, results of operations, uses of cash and other measures of financial performance. All forward-looking statements involve risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Risks and uncertainties include, without limitation, the effect of economic conditions in the markets in which we operate,the financial condition of our customers and suppliers; delays and disruption in delivery of materials and services from suppliers; potential intellectual property infringement by third parties; potential legal proceedings initiated against us; the effect of changes in tax, environmental and other laws and regulations and political conditions in states and countries in which we sell our products and other factors beyond our control. These forward-looking statements speak only as of the date of this release and we undertake no obligation to update or revise any forward-looking statements after we distribute this release. For additional information identifying factors that may cause actual results to vary materially from those stated in the forward-looking statements, see our reports on Forms 10-K, 10-Q and 8-K filed with the SEC from time to time, including, but not limited to, the information included in our Forms 10-K and 10-Q under the headings “Business”,“Risk Factors”,“Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” and in the notes to the financial statements included in our Forms 10-K and 10-Q.